In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis

Basit Öğe Kaydı
dc.authoridOzgocmen, Salih/0000-0002-4860-452X
dc.authoridOzgocmen, Salih/0000-0002-4860-452X
dc.authorwosidFadillioglu, Ersin/K-3817-2019
dc.authorwosidOzgocmen, Salih/K-4680-2019
dc.authorwosidOzgocmen, Salih/K-9588-2015
dc.contributor.authorOzgocmen, S
dc.contributor.authorArdicoglu, O
dc.contributor.authorErdogan, H
dc.contributor.authorFadillioglu, E
dc.contributor.authorGudul, H
dc.date.accessioned2024-08-04T20:14:44Z
dc.date.available2024-08-04T20:14:44Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to compare the in vivo effects on free radical metabolism of 2 nonsteroidal anti-inflammatory drugs (NSAIDs): tenoxicam, an oxicam preferentially cyclooxygenase-1 (COX1) inhibitor, and celecoxib, a sulfonamide selective COX-2 inhibitor. The serum levels of oxidative stress-related enzymes (ie, xanthine oxidase (XO), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px)), of a lipid peroxidation marker (malondialdehyde (MDA)), and of nitric oxide (NO) in patients with knee osteoarthritis were studied at baseline and after a 4-wk course of treatment with celecoxib (n = 11) and tenoxicam (n = 12). Celecoxib-treated patients had significant decrease in nitrite levels (p = 0.043), whereas SOD, XO, GSH-Px enzyme activities, and MDA levels did not change significantly compared to baseline. Tenoxicam-treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH-Px enzyme activities, and MDA levels were unchanged from baseline. There was significant correlation between the patients' (n = 23) Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index, WOMAC-pain scores, and MDA levels (r = 0.50, p = 0.014) and the patients' WOMAC-stiffness scores and XO enzyme activity (r = 0.46, p = 0.027) at baseline. Significant improvement was found in pain-VAS, patients' global assessment, and WOMAC pain, stiffness, and physical function scores in celecoxib and tenoxicam- treated groups. In summary, our study revealed that tenoxicam may have antioxidant effects, and that celecoxib and tenoxicam may reduce nitrite levels, indicating an alteration of NO pathways.en_US
dc.identifier.endpage143en_US
dc.identifier.issn0091-7370
dc.identifier.issn1550-8080
dc.identifier.issue2en_US
dc.identifier.pmid15943176en_US
dc.identifier.scopus2-s2.0-18744384078en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage137en_US
dc.identifier.urihttps://hdl.handle.net/11616/93938
dc.identifier.volume35en_US
dc.identifier.wosWOS:000229123600004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Clinical Scientistsen_US
dc.relation.ispartofAnnals of Clinical and Laboratory Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectosteoarthritisen_US
dc.subjectcelecoxiben_US
dc.subjecttenoxicamen_US
dc.subjectoxidative stressen_US
dc.subjectfree radicalsen_US
dc.subjectnitric oxideen_US
dc.titleIn vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu